|
| Press Releases |
|
 |
|
| Wednesday, March 11, 2026 |
|
|
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis |
| Everest Medicines (1952.HK) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated Hospital of Sun Yat-sen University, marking a milestone in patient access in the region. According to reports, on the day the first prescription was issued in mainland China, VELSIPITY(R) was simultaneously prescribed in eight tertiary hospitals across seven key cities'Guangzhou, Shanghai, Hangzhou, Xi'an, Chongqing, Beijing, and Nanjing'achieving immediate coverage of patients in major regions nationwide on its launch day. more info >> |
|
|
云顶新耀维适平(R)中国大陆首张处方落地 填补中重度溃疡性结肠炎治疗空白 |
| 云顶新耀（01952.HK）宣布，旗下自身免疫性疾病领域核心产品维适平(R)（精氨酸艾曲莫德片，VELSIPITY(R)）中国大陆首张处方在3月9日于中山大学附属第一医院开出，标志着这款创新疗法正式进入中国临床应用阶段。 more info >> |
|
|
雲頂新耀維適平(R)中國大陸首張處方落地 填補中重度潰瘍性結腸炎治療空白 |
| 雲頂新耀（01952.HK）宣佈，旗下自身免疫性疾病領域核心產品維適平(R)（精氨酸艾曲莫德片，VELSIPITY(R)）中國大陸首張處方在3月9日於中山大學附屬第一醫院開出，標志著這款創新療法正式進入中國臨床應用階段。 more info >> |
|
| Wednesday, February 25, 2026 |
|
|
Everest Medicines Shareholders Pass Resolutions Including Commercialization Service Agreement at EGM |
| Everest Medicines shareholders passed all proposed resolutions at an extraordinary general meeting (the 'EGM') held virtually on February 24, 2026, the company said in a filing. more info >> |
|
|
雲頂新耀股東特別大會通過商業化服務協議等決議案 |
| 雲頂新耀有限公司（1952.HK）宣佈，於2026年2月24日以線上虛擬會議形式舉行的股東特別大會順利召開，會議所提呈的全部決議案均獲股東正式通過。 more info >> |
|
|
云顶新耀股东特别大会通过商业化服务协议等决议案 |
| 云顶新耀有限公司（1952.HK）宣布，于2026年2月24日以线上虚拟会议形式举行的股东特别大会顺利召开，会议所提呈的全部决议案均获股东正式通过。 more info >> |
|
| Friday, February 6, 2026 |
|
|
Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis |
| Everest Medicines today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. more info >> |
|
|
雲頂新耀維適平(R)獲中國國家藥品監督管理局批准上市 為中重度潰瘍性結腸炎治療提供新選擇 |
| 2026年2月6日，雲頂新耀今日宣佈，中國國家藥品監督管理局（NMPA）已批准維適平(R)（精氨酸艾曲莫德片, VELSIPITY(R)）的新藥上市許可申請（NDA），用於治療對傳統治療或生物制劑應答不充分、失應答或不耐受的中度至重度活動性潰瘍性結腸炎成人患者。 more info >> |
|
|
云顶新耀维适平(R)获中国国家药品监督管理局批准上市 为中重度溃疡性结肠炎治疗提供新选择 |
| 2026年2月6日，云顶新耀今日宣布，中国国家药品监督管理局（NMPA）已批准维适平(R)（精氨酸艾曲莫德片, VELSIPITY(R)）的新药上市许可申请（NDA），用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎成人患者。 more info >> |
|
| Thursday, February 5, 2026 |
|
|
Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013 |
| Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
COSCO SHIPPING Ports Announces 2025 Annual Results
Mar 18, 2026 18:36 HKT/SGT
|
|
|
HKTDC launches GreenBiz HK campaign in Bangkok
Mar 18, 2026 18:30 HKT/SGT
|
|
|
中遠海運港口公佈2025年全年業績
Mar 18, 2026 18:26 HKT/SGT
|
|
|
盈立證券勇奪港交所兩項殊榮 港資科技券商實力有目共睹
Mar 18, 2026 17:48 HKT/SGT
|
|
|
盈立证券勇夺港交所两项殊荣 港资科技券商实力有目共睹
Mar 18, 2026 17:48 HKT/SGT
|
|
|
Sunshine Insurance Delivers 2025 Results: Customer Operation System Continues to Innovate
Mar 18, 2026 17:40 HKT/SGT
|
|
|
中远海运港口公布2025年全年业绩
Mar 18, 2026 17:12 HKT/SGT
|
|
|
The 'New Sunshine Strategy' Gains Tangible Results, Sunshine Insurance Group Delivers a High-quality 2025 Performance Report
Mar 18, 2026 16:54 HKT/SGT
|
|
|
FILMART and EntertainmentPulse 2026 open today
Mar 18, 2026 17:30 JST
|
|
|
AdsDrama Introduces Short Drama Advertising Platform Amid Growth in Digital Content Monetization
Mar 18, 2026 15:30: JST
|
|
|
AdsDrama Introduces Short Drama Advertising Platform Amid Growth in Digital Content Monetization
Mar 18, 2026 14:30 HKT/SGT
|
|
|
三菱重工、新しい経営方針「ITO」の実践による優秀事例を顕彰
Mar 18, 2026 14:00: JST
|
|
|
MHI Commends Outstanding Examples of Implementing its New Management Policy "ITO"
Mar 18, 2026 13:09 JST
|
|
|
Chuangxin Industries Announces 2025 Annual Results
Mar 18, 2026 09:30 HKT/SGT
|
|
|
創新實業公佈2025年全年業績 收入及利潤穩步增長
Mar 18, 2026 09:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
